Loading company
Alkermes plc.
ALKS · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
Next earnings: October 27, 2026
$40.16-1.7%Sep 28 close
- 1M
- -15.3%
- 6M
- +36.6%
- 1Y
- +38.3%
- 5Y
- +25.2%
Alkermes plc. is the 10th largest of 78 graded companies. Showing 5 of them, including ALKS itself. 6 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries LimitedTEVA | A | $45.3B | $17.3B | 4.1% | $1.3B | 64.80 |
| Haleon plcHLN | B+ | $41.1B | $14.6B | 15.1% | $3.1B | 18.70 |
| Takeda Pharmaceutical Company LimitedTAK | B | $30.3B | $28.7B | -3.4% | $5.5B | 44.10 |
| Zoetis Inc.ZTS | A+ | $29.5B | $9.5B | 27.5% | $2.3B | 11.77 |
| Alkermes plc.ALKS | B | $6.7B | $1.7B | 4.0% | $221.7M | 105.68 |
73 more drug manufacturers specialty and generic companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Alkermes plc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
ALKS · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
Next earnings: October 27, 2026
$40.16-1.7%Sep 28 close